Overcoming the myths of esketamine administration: different and not difficult
Frontiers in Psychiatry November 23, 2023 Florian Buchmayer, Siegfried Kasper 19 citations
Intranasal esketamine for treatment-resistant depression has been introduced and approved by the FDA and EMA in 2019 and 2020, respectively. Since then, the administration practices were found different among countries. Major depression has a high impact on many humans lives worldwide and more than a third of treated people are not responding after several treatment attempts. Additional...